Nasal Vaccines Market, By Vaccine Type (Live attenuated vaccines, Inactivated vaccines, Subunit, recombinant, and conjugate vaccines, and Others (such as DNA vaccines, viral vector vaccines, etc.)), By Application (Influenza, COVID-19, Other respiratory i

Nasal vaccine is a vaccine administered through the nose that stimulates an immune response without an injection. A vaccine dose is given via nose, rather than orally or through the arm. While several versions of a nasal vaccine are in development, most are in preclinical stages. A nasal vaccine is touted to have the ability to end the cycle of transmission, stop infection, and stop lung damage, including other adverse effects as the dose is administered through the nose, where the virus first enters the body. Thus, market players are focusing on developing safe/effective nasal vaccines.

Market Dynamics:

The rising burden of respiratory diseases or infections, outbreak of COVID-19, increasing focus on the development of safe and effective vaccines, increasing demand for safe and effective vaccines, and increasing research and development activities are the major factors expected to propel the growth of the global nasal vaccines market over the forecast period.

For instance, in January 2023, Bharat Biotech, an Indian-based global biopharmaceutical company announced the launch of India’s first intra-nasal COVID-19 vaccine, iNCOVACC for a primary as well as heterologous (mix-and-match) booster dose in India. It was the first nasal COVID-19 vaccine that was approved both as a primary two-dose regimen, and a heterologous booster after two doses of Covishield or Covaxin. It is approved by the Drugs Control General of India (DCGI) as a heterologous booster dose. The new iNCOVACC vaccine can potentially revolutionize the battle against COVID-19 infection.

Key Features of the Study:

• This report provides an in-depth analysis of the global nasal vaccines market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nasal vaccines market based on the following parameters, company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., SINOVAC, Bharat Biotech, Altimmune, FluGen Inc., Vaxart, Intravacc, Gamma Vaccines Pty Ltd., and BioNTech SE
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global nasal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal vaccines market

• By Vaccine Type:
• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit, Recombinant, and Conjugate Vaccines
• Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
• By Application:
• Influenza
• COVID-19
• Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
• Others (such as Cholera, Typhoid, etc.)
• By Distribution Channel:
• Public
• Private
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• AstraZeneca,
• GlaxoSmithKline plc
• Pfizer Inc.
• Serum Institute of India Pvt. Ltd.
• SINOVAC
• Bharat Biotech
• Altimmune
• FluGen Inc.
• Vaxart
• Intravacc
• Gamma Vaccines Pty Ltd.
• BioNTech SE